Patents by Inventor Takuya YOKOSAKA

Takuya YOKOSAKA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ARYL OR HETEROARYL DERIVATIVE
    Publication number: 20230167073
    Abstract: A compound indicated by formula (I) or a pharmacologically acceptable salt thereof is provided as a compound that can be a therapeutic or prophylactic drug for TRPC6-related diseases, such as nephrotic syndrome, membranous nephropathy, acute renal failure, septicemia, chronic renal failure, diabetic nephropathy, pulmonary hypertension, acute lung injury, heart failure, malignant tumor, and muscular dystrophy. (In the formula, Ar1, Ar2, X1-X3, R1, R3, R7, R8, L1, and L2 are as defined in the specifications.
    Type: Application
    Filed: April 15, 2021
    Publication date: June 1, 2023
    Applicant: Teijin Pharma Limited
    Inventors: Sakae SUGIYAMA, Takuya YOKOSAKA, Kunio MINAMIZONO, Asahi KAWANA, Toshiyuki KANEKO, Akinobu MARUYAMA, Kosuke SASAKI, Shinnosuke HOSODA, Masaki KOSHIMIZU, Susumu TAKEUCHI, Kenta KATO, Nagasree CHAKKA, Brett M. JOHNSON, Ryan D. WHITE, Wei ZHAO
  • Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof
    Patent number: 11084814
    Abstract: The purpose of the present invention is to provide a compound that has excellent CDK4/6 inhibitory activity. The present invention is a compound represented by formula (I) or a pharmaceutically acceptable salt of the compound.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: August 10, 2021
    Assignee: Teijin Pharma Limited
    Inventors: Tsuyoshi Mizuno, Tomohiro Shimada, Gen Unoki, Akinobu Maruyama, Kosuke Sasaki, Takuya Yokosaka, Hiroshi Takahashi, Kyohei Horie, Yuri Sakai
  • PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
    Publication number: 20190367510
    Abstract: The purpose of the present invention is to provide a compound that has excellent CDK4/6 inhibitory activity. The present invention is a compound represented by formula (I) or a pharmaceutically acceptable salt of the compound.
    Type: Application
    Filed: November 27, 2017
    Publication date: December 5, 2019
    Applicant: Teijin Pharma Limited
    Inventors: Tsuyoshi MIZUNO, Tomohiro SHIMADA, Gen UNOKI, Akinobu MARUYAMA, Kosuke SASAKI, Takuya YOKOSAKA, Hiroshi TAKAHASHI, Kyohei HORIE, Yuri SAKAI
  • Pyrido[3,4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof
    Patent number: 10124004
    Abstract: The purpose of the present invention is to provide a compound having an excellent CDK4/6 inhibiting activity. The present invention is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: November 13, 2018
    Assignee: Teijin Pharma Limited
    Inventors: Tsuyoshi Mizuno, Tomohiro Shimada, Gen Unoki, Masaru Ebisawa, Susumu Takeuchi, Kunio Minamizono, Kosuke Sasaki, Takuya Yokosaka, Junji Igarashi, Akinobu Maruyama, Hiroshi Takahashi, Kyohei Horie, Yuri Sakai
  • PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
    Publication number: 20180161329
    Abstract: The purpose of the present invention is to provide a compound having an excellent CDK4/6 inhibiting activity. The present invention is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 27, 2016
    Publication date: June 14, 2018
    Applicant: Teijin Pharma Limited
    Inventors: Tsuyoshi MIZUNO, Tomohiro SHIMADA, Gen UNOKI, Masaru EBISAWA, Susumu TAKEUCHI, Kunio MINAMIZONO, Kosuke SASAKI, Takuya YOKOSAKA, Junji IGARASHI, Akinobu MARUYAMA, Hiroshi TAKAHASHI, Kyohei HORIE, Yuri SAKAI